Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
about
Radiotherapy and "new" drugs-new side effects?Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodellingHER2 signaling pathway and trastuzumab cardiotoxicity.Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.Cardiovascular disease after cancer therapy.Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.Targeted therapies in breast cancer: are heart and vessels also being targeted?Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeuticsEfficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysisTimely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge.The role of targeted therapy and biomarkers in breast cancer treatment.Cancer drugs and the heart: importance and management.Drug-induced oxidative stress and toxicity.Clinical practice-changing trials: the HERA study paradigm.Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer.Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.First annual Canadian Cardiac Oncology Network conference.Trastuzumab (herceptin): a retrospective analysis of the effects of long-term application in a series of patients with breast cancer.Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.Zoledronic acid and atrial fibrillation in cancer patients.Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).Trastuzumab-related cardiac events in the treatment of early breast cancer.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesMechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
P2860
Q26861498-9E747B6D-4549-4C97-9B6E-C65916C31FE3Q31039304-4492F3BE-3D69-4BEF-9AE3-42589DD890B1Q33595716-A853B5BB-D289-4FB7-96A0-7B2B6A55A58EQ33789572-FF746F8C-7950-4703-8687-9D665AA65D08Q33930241-A68DA639-4556-4FA9-AE53-CBAD5B87D702Q34145896-F15CCDC4-A621-44C9-A8BE-CE7DD2CEB3F2Q34328064-68B1CD81-6A3E-44E8-AF2E-BBF851F7C49AQ34551761-97DAEA39-9916-4499-A6A8-F41311E4EBF3Q34604429-2CD5ED34-AE17-4D3E-8301-98CB96994A7AQ34625462-11B9F3C1-438B-448A-B435-DF5FACC245BDQ34626878-2092E9A0-FDDF-48B7-BB52-A255087D74E4Q34694972-235F4346-D8BE-4EB2-B680-472EEE71B744Q36245324-51239D7B-0D6E-4051-AA3B-2F23EDC6E578Q36396421-ED3D2794-5282-49D7-A575-C8663CFBF055Q36824869-81F0498E-F03E-44DA-9A5E-8403A20D1C8AQ37926954-177884C1-6491-4CBB-8B19-3BA4B7ECD5D7Q37973320-1766D110-2A42-44F1-9267-6BF4159C20A9Q38018259-646CC946-3043-4FB9-BE0C-A754ACDE7BE7Q38025824-773AE0D2-7910-435E-841F-71DE0384927EQ38037517-2EE0D154-4880-44C5-A20F-639A8EF2B91EQ38153774-C7559550-CFCD-4A6C-B754-3B0397FEAE51Q38364887-FA65475D-CBED-4E23-9A48-D505D2E00EE9Q39061588-1844CF50-0D76-46BE-B8D0-0DBD30F9F750Q39314472-45B9EFE6-E13B-4814-BDE2-FBA7B0F9C367Q39468098-F123A270-F972-4086-8613-4BA04C65E855Q45917757-2F7B12AB-F5F6-4F51-91C7-93125CC232B3Q46958045-54CA7D64-DF3B-47A9-A42A-ED574917E5E4Q50589569-99C86344-6A48-4664-B626-ACBE391783EFQ51573753-BDD1482B-C00A-4DE7-AFAA-A56B3CAFC979Q53655466-590A1C17-922E-498E-A01A-9E158BAEEA08Q54705428-691E9EFD-05AC-4D75-97AC-7F4C1A672AB9Q57057499-27A56C40-1789-41D0-8869-C94AE641D528Q57069976-ECDCEEE7-D293-432D-A2C2-6B362DAF8B77
P2860
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
@en
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
@nl
type
label
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
@en
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
@nl
prefLabel
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
@en
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
@nl
P50
P1433
P1476
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
@en
P2093
Thomas Suter
P2888
P356
10.1007/S11523-009-0112-2
P577
2009-04-01T00:00:00Z